PBYI vs SRZN
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
PBYI presents a stable Piotroski F-Score of 4/9, but the stock is currently trading at a significant premium to its Graham Number ($5.96) and Intrinsic Value ($4.27). While the company maintains impressive gross margins (74.53%) and a strong ROE (27.97%), these are offset by a concerning -34.4% YoY earnings growth. With a technical trend score of 10/100 and an analyst target price of $5.00, the current price of $7.24 appears fundamentally overextended. Bearish insider activity from the CEO and CFO further suggests a lack of confidence in near-term upside.
SRZN exhibits critical financial instability, highlighted by a Piotroski F-Score of 1/9, indicating severe fundamental weakness. The company is operating with negative equity (Price/Book: -1.64) and an unsustainable Price/Sales ratio of 106.77, suggesting the current valuation is entirely speculative. While the current ratio of 9.22 provides a temporary liquidity cushion, the combination of declining revenue (-19.4% YoY) and massive earnings misses (most recent surprise -678.8%) points to a failing operational model. The recent price surge is disconnected from all deterministic health and value metrics.
Compare Another Pair
Related Comparisons
PBYI vs SRZN: Head-to-Head Comparison
This page compares Puma Biotechnology, Inc. (PBYI) and Surrozen, Inc. (SRZN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.